Joseph Schwartz, an analyst from Leerink Partners, reiterated the Buy rating on Wave Life Sciences. The associated price target remains the same with $24.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Joseph Schwartz has given his Buy rating due to a combination of factors that signal potential growth for Wave Life Sciences. The company has reported its second-quarter results and provided updates on its key programs, specifically WVE-006 for alpha-1-antitrypsin deficiency and WVE-007 for obesity. These programs are set to have significant data readouts in the coming quarters, which are expected to be pivotal for the company’s future performance.
Schwartz believes that the upcoming data releases could serve as major catalysts for Wave Life Sciences, offering multiple opportunities for stock appreciation in the latter half of the year and beyond. Despite a lackluster stock performance in the first half of the year, largely due to perceived inactivity, the anticipated updates could reignite investor interest and engagement. This potential for significant value increase justifies the Buy rating, with a price target that remains unchanged.
In another report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $24.00 price target.
WVE’s price has also changed moderately for the past six months – from $12.060 to $8.160, which is a -32.34% drop .